Neuropilin-1 is a host factor for SARS-CoV-2 infection

James L. Daly(University of Bristol), Boris Simonetti(University of Bristol), Katja Klein(University of Bristol), Kai‐En Chen(The University of Queensland), Maia Kavanagh Williamson(University of Bristol), Carlos Antón-Plágaro(University of Bristol), Deborah K. Shoemark(University of Bristol), Lorena Simón‐Gracia(University of Tartu), Michael Bauer(University of Zurich), Réka Hollandi(HUN-REN Szegedi Biológiai Kutatóközpont), Urs F. Greber(University of Zurich), Péter Horváth(University of Helsinki), Richard B. Sessions(University of Bristol), Ari Helenius(ETH Zurich), Julian A. Hiscox(University of Liverpool), Tambet Teesalu(University of Tartu), David A. Matthews(University of Bristol), Andrew D. Davidson(University of Bristol), Brett M. Collins(The University of Queensland), Peter J. Cullen(University of Bristol), Yohei Yamauchi(University of Bristol)
Science
October 20, 2020
Cited by 1,358Open Access
Full Text

Abstract

Another host factor for SARS-CoV-2 Virus-host interactions determine cellular entry and spreading in tissues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the earlier SARS-CoV use angiotensin-converting enzyme 2 (ACE2) as a receptor; however, their tissue tropism differs, raising the possibility that additional host factors are involved. The spike protein of SARS-CoV-2 contains a cleavage site for the protease furin that is absent from SARS-CoV (see the Perspective by Kielian). Cantuti-Castelvetri et al. now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity. NRP1 is abundantly expressed in the respiratory and olfactory epithelium, with highest expression in endothelial and epithelial cells. Daly et al. found that the furin-cleaved S1 fragment of the spike protein binds directly to cell surface NRP1 and blocking this interaction with a small-molecule inhibitor or monoclonal antibodies reduced viral infection in cell culture. Understanding the role of NRP1 in SARS-CoV-2 infection may suggest potential targets for future antiviral therapeutics. Science , this issue p. 856 , p. 861 ; see also p. 765


Related Papers

No related papers found

Powered by citation graph analysis